Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene in Novartis deal

Novartis (SWX:NOVN) acquired an exclusive global license, excluding Canada, to CELG's d-methylphenidate, a chirally pure form of Ritalin, to treat attention deficit disorder and attention deficit hyperactivity

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE